Bifidobacterium breve

bacteria

What is it

Bifidobacterium breve is a probiotic bacterium naturally present in the gut of breastfed infants and, in lower amounts, in adults. It is used in probiotic supplements for infant and pediatric digestive health, allergic conditions, and immune support.

How it works

B. breve colonizes the colon and ferments complex carbohydrates, including human milk oligosaccharides (HMOs), producing short-chain fatty acids that lower colonic pH and support colonocyte energy supply. Its ability to metabolize HMOs makes it well-suited to the breastfed infant gut. B. breve interacts with the developing gut-associated immune system, helping shape early immune tolerance and barrier function. It produces lactate and acetate that inhibit growth of many pathogenic bacteria and may support the establishment of a stable, diverse microbiota in early life. Some strains may also influence the gut-brain axis and intestinal motility. Different strains have different documented uses. Strain BBG-001 (M-16V) has been studied extensively in preterm infants for prevention of necrotizing enterocolitis and as part of multi-strain neonatal protocols. Strain A1 has been studied for cognitive outcomes in adults. As with other probiotics, strain-level effects do not necessarily generalize across the species.

Evidence for 4 uses

AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.

Necrotizing enterocolitis prevention (preterm infants)

Grade B

Good evidence

Multi-strain probiotic protocols including B. breve have been studied in preterm infants for prevention of necrotizing enterocolitis and late-onset sepsis. Meta-analyses suggest modest benefit, though results vary and use requires neonatal specialist supervision.

Infant colic and functional GI symptoms

Grade C

Moderate evidence

Some trials of B. breve in infants show modest improvement in colic, regurgitation, and stool consistency. Evidence is less extensive than for L. reuteri DSM 17938.

Allergic disease prevention (infants)

Grade C

Moderate evidence

B. breve in early-life probiotic protocols has been studied for prevention of eczema and food allergy with mixed results. Effects appear modest and may depend on combination with other strains.

Cognitive function (strain A1)

Grade C

Moderate evidence

Preliminary trials of B. breve A1 suggest modest improvement in memory or cognitive scores in older adults. Evidence is early.

3 commercial forms

B. breve M-16V (BBG-001)

Acid-stable, well-studied in preterm infants

Most-studied strain for neonatal applications. Used in NICU probiotic protocols in some countries.

B. breve A1

Studied for cognitive applications

Developed for memory and cognitive outcomes in older adults.

B. breve BR-03

Common in multi-strain blends

Used in commercial adult and pediatric probiotic formulations.

Dosage

There is no RDA for probiotics. Pediatric studies of B. breve typically use 100 million to 10 billion CFU per day. Adult supplement doses commonly range from 1 to 20 billion CFU per dose, often combined with other Bifidobacterium and Lactobacillus strains. Preterm neonatal protocols use carefully titrated doses under specialist supervision.

When and how to take it

B. breve can be taken with or without food. Taking with a small meal may improve survival through the stomach. For infants, drops or sachets are typically given once daily. For adult applications, consistency over weeks matters more than precise timing. Separate from antibiotic doses by at least 2 hours. Refrigeration extends shelf life for most strains.

Food sources

Food	Amount	%DV
Some infant formulas with added Bifidobacterium	Variable; check label	—
Yogurts with added Bifidobacterium	Variable; B. breve specifically uncommon	—
Human breast milk (natural source)	Natural transmission to infant gut	—

Safety

B. breve is generally well tolerated. Mild gas, bloating, or digestive changes can occur initially. Serious adverse events are rare in healthy people, though probiotic bacteremia has been documented in critically ill or extremely premature infants and in immunocompromised adults. There is no established Tolerable Upper Intake Level.

Who should be cautious

Severely immunocompromised individuals, those with central venous catheters, and critically ill patients should consult their physician before taking live probiotic supplements. Probiotic use in premature or critically ill infants should only occur under specialist neonatal supervision. Pregnant and breastfeeding women generally tolerate B. breve well.

Interactions

Antibiotics can kill probiotic organisms; separate doses by at least 2 hours. Immunosuppressive medications may increase the small risk of bacterial translocation. No well-documented interactions with most supplements or medications. Combining with prebiotic fibers may enhance B. breve growth and persistence in the gut.

Frequently asked questions

Why is B. breve common in infant probiotics?⌄

B. breve naturally dominates the gut of breastfed infants and is well adapted to metabolize human milk oligosaccharides. This makes it a logical choice for infant-targeted formulations.

Should I give B. breve to my preterm baby?⌄

Probiotic use in preterm infants should only occur under specialist neonatal supervision. Some NICUs use protocols including B. breve, but this is not appropriate for parents to start independently.

Does B. breve help adults?⌄

Most B. breve research has focused on infants, but some adult trials (particularly with strain A1) explore cognitive and digestive applications. Evidence in adults is less extensive than in infants.

Can B. breve survive the adult stomach?⌄

Modern supplement-grade strains are selected for acid tolerance, and some are delivered in protective capsules. A meaningful fraction of cells typically reaches the colon alive.

How long until I see effects?⌄

For acute applications, effects may appear within days. For chronic concerns or in infants with colic, allow several weeks of consistent use.

References

Wikidata: Bifidobacterium breve — Wikidata link

Track Bifidobacterium breve with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.

Coming to App Store

Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments — talk to your doctor before starting any new supplement, especially if you're pregnant, breastfeeding, on medications, or managing a chronic condition.